Anti-HIV-1 Chimeric Antigen Receptor (CAR)-T Cell Therapy(Shenzhen City of Regeneration Biomedical Technology)

抗HIV-1嵌合抗原受体T细胞疗法（深圳市再生之城生物医药技术）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-HIV-1 Chimeric Antigen Receptor (CAR)-T Cell Therapy(Shenzhen City of Regeneration Biomedical Technology)
Drug Alias NameVC-CAR T
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionHIV envelope protein gp120 inhibitors
TargetsHIV envelope protein gp120
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesShenzhen Regeneration City Biomedical Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShenzhen Regeneration City Biomedical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A